Who's Developing What in Global Biopharmaceuticals?

Biopharmaceuticals, Pharmaceuticals, Healthcare, Company, Market

Publication Date	September 2008
Publisher	Espicom
Product Type	Report
Pages	436
ISBN Number	978-1-85822-332-6
Product Code	ESP00568

Price

£695.00
approximately: $1,016 | €762

PDF

Order above formats by FAX

Summary

A critical assessment of leading companies, their research, products, partners and performance.

The biopharmaceutical R&D sector is taking an ever more important role in the minds of industry and investors. The potential to fundamentally alter treatment regimes and cure, rather than symptomatically treat, many life-threatening conditions grows greater, but questions remain:

Who are the companies that are leading development in this critical area?
What is their area of expertise?
How substantial is their current product line-up or pipeline projects?
With whom are they collaborating?
How can you assess their strengths and weaknesses?

Who's Developing What in Global Biopharmaceuticals? is a new 475 page management guide to 50 significant companies working in the field. From their structure, through collaboration and detailed pipeline evaluation, the report provides an unmatchable window to the future biopharmaceutical corporate environment.

Important areas covered, where available, for each company include:

Key Personnel - List of key management
Company Overview
Milestones - Summary table of key events in the company's history
R&D Pipeline - Products/research by phase and indication
Technology - Novel discovery/production technology platforms
Agreements - Who's working with whom? Important alliances identified
Key Financial Data - Essential P&L/funding data
Appraisal & Evaluation - A critical assessment of the company's platform, pipeline and corporate environment

Answering key questions such as...

With which major pharmaceutical companies is French company Evotec working, and on what?
Optimer Pharmaceuticals has eight products in development - what stage are they at and for what are they indicated?
What benefit has Astex Therapeutics' Pyramid drug discovery platform brought to the company?

Affymax
Ambit Biosciences
Ambrx
Amylin Pharmaceuticals
Arana Therapeutics
ARCA biopharma
ARIUS Research
ARYx Therapeutics
Astex Therapeutics
BioVex
BioXell
Bruin Pharmaceuticals
Cellectis
CombinatoRx
Deltanoid Pharmaceuticals
Diatos
Evotec
FivePrime Therapeutics
Genmab A/S
Idenix Pharmaceuticals
Ikaria
Infinity Pharmaceuticals
Intercytex
Ironwood Pharmaceuticals
KAI Pharmaceuticals
Kalypsys
Kereos
Micromet
Molecular Insight Pharmaceuticals
Neuromed Pharmaceuticals
Novexel
NPS Pharmaceuticals
Optimer Pharmaceuticals
Palatin Technologies
PharmaMar
Prana Biotechnology
Replidyne
S*BIO
Sosei
Speedel Pharmaceuticals
Synta Pharmaceuticals
Syntaxin
Takara Bio
Theravance
Tranzyme Pharma
Trimeris
Trubion Pharmaceuticals
ViroPharma
WILEX
Xencor

Content

Affymax
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Affymax R&D Pipeline, August 2008
- Haematology
- Hematide
- Other Indications
- Innotide
- Adeptide
- Angiotide
- Technology
- Agreements
- Takeda
- EntreMed
- Nektar
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
AmbitBiosciences
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Ambit Biosciences R&D Pipeline, August 2008
- Oncology
- AC220
- AC480
- AURORA Kinase Inhibitors
- BRAF Kinase Inhibitors
- JAK2
- ABL (T3 151)
- Technologies
- Kinase Profiling Platform
- Agreements
- Cephalon
- Bristol-Myers Squibb
- Medarex
- AstraZeneca
- GlaxoSmithKline
- Roche
- Pfizer
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Ambrx
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Human Growth Hormone
- ARX201
- Technologies
- ReCODE Technology
- Patents
- Agreements
- Merck S erono
- Eli Lilly
- Roche
- Merck & Co
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Amylin Pharmaceuticals
- Key Personnel
- Company Overview
- Milestones
- Marketed Products
- Metabolism
- BYETTA (exenatide, AC2993 (synthetic exendin-4)) injection
- SYMLIN (pramlintide acetate) injection
- R&D Pipeline
- Amylin Pharmaceuticals R&D Pipeline, August 2008
- Metabolism
- Diabetes
- Obesity
- Discontinued Products
- Cardiology
- AC3056
- AC2592
- Agreements
- Eli Lilly
- Alkermes
- Nastech
- PsychoGenics
- Kelaroo
- BioSeek
- Xenome
- Johnson & Johnson
- Aventis
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Arana Therapeutics
- Key Personnel
- Table of Contents
- Company Overview
- Milestones
- R&D Pipeline
- Arana Therapeutics R&D Pipeline, August 2008
- Autoimmune and Inflammatory Diseases
- ART621
- PMX53
- Oncology
- ART104
- ART010
- ART150
- ART140
- ART101
- ART160
- Technologies
- Protein Engineering Platforms
- Patents
- Patent Families Revenue Generating
- Patent Families Product Development
- Agreements
- Vegenics
- AVEO Pharmaceuticals
- CSL Limited
- GlaxoSmithKline
- Centocor
- Abbott
- EvoGenix Pty
- Kyowa Hakko
- greenovation Biotech
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
ARCA biopharma
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Cardiology
- Bucindolol
- Agreements
- Laboratory Corporation of America Holdings
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
ARIUS Research
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Table of Contents
- ARIUS Research R&D Pipeline, August 2008
- Oncology
- CD44 Cancer Stem Cell Program/ARH460-16-2
- Trop-2 Signal Transduction Program/AR47A6.4.2
- CD59 Complement Inhibitor Program/AR36A36.11.1
- CD9 Cancer Stem Cell Program/AR40A746.2.3
- AR7BD-33-11A
- Others
- Technologies
- Patents
- Agreements
- Centro de Immunologia M olecular (CIMAB)
- Xerion Pharmaceuticals AG
- PDL B ioPharma
- Medarex
- Oxford B ioMedica
- Genentech
- Takeda
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
ARYx Therapeutics
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- ARYx Therapeutics R&D Pipeline, August 2008
- Gastrointestinal
- ATI-7505
- ATI-24,000
- Cardiology
- ATI-5923
- ATI-2042
- Antipsychotic
- ATI-9242
- Metabolism
- ATI-20,000
- Technologies
- Drug Design Technology
- Design and Synthesis of Ideal Metabolites
- RetroMetabolic Engineering
- Evaluation of Metabolism
- Patents
- Agreements
- Procter & Gamble
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Astex Therapeutics
- Table of Contents
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Astex Therapeutics R&D Pipeline, August 2008
- Oncology
- AT7519
- AT9283
- AT9311
- AT13387
- AT13148
- Technologies
- Drug Discovery Platform
- PYRAMID
- Patents
- Agreements
- Technology
- Cambridge Crystallographic Data Centre
- Daresbury Analytical Research and Technology Service
- Global Phasing
- Rigaku/MSC
- Daylight Chemical Information Systems
- Maybridge
- Product
- Janssen Research Foundation
- Aventis
- Mitsubishi Pharma
- AstraZeneca
- Institute of Cancer Research and Cancer Research Technology
- The Wellcome Trust, the Institute of Cancer Research, Cancer Research Technology and GlaxoSmithKline
- Schering AG
- Fujisawa Pharmaceutical
- Boehringer Ingelheim
- Novartis
- Pfizer
- University of Newcastle upon Tyne/Cancer Research Technology
- GlaxoSmithKline
- Janssen Pharmaceutica
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Bio Vex
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- BioVex R&D Pipeline, August 2008
- Oncology
- OncoVEX GM-CSF
- Virology
- Table of Contents
- ImmunoVEXHSV2
- Patents
- Agreements
- Wyeth Pharmaceuticals
- Merck & Co
- National Institutes of Health
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
BioXel
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- BioXell R&D Pipeline, August 2008
- Urology
- BXL628/Elocalcitol
- Pain Relief
- MNAC13
- Musculoskeletal
- BXL093
- Inflammation
- TREM-1
- TREM Programme
- BXL746
- Technologies
- The VD3 platform
- MNAC13 Platform
- The TREM platform
- Agreements
- Roche
- Lay Line Genomics
- Merck & Co
- Galapagos/ProSkelia
- Zambon
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Bruin Pharmaceuticals
- Key Personnel
- Company Overview
- R&D Pipeline
- Cardiology
- D-4F
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Cellectis
- Table of Contents
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Oncology
- Meganucleases targeting p53
- Meganucleases targeting XPC
- Immunology
- Meganuclease targeting IL2RG
- Meganuclease targeting RAG1
- Patents
- Agreements
- Artemis Pharmaceuticals
- Deltagen
- Nucleis
- Fermentas
- Diversa
- Regeneron Pharmaceuticals
- Murinus
- Ascenion
- Lexicon Genetics
- Celliance
- Xenogen B iosciences
- Ozgene
- Biogen Idec
- AstraZeneca
- Shire Pharmaceuticals
- Celonic
- Genentech
- GlaxoSmithKline
- Laboratoires S ervier
- TransGenic
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Combinato Rx
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- CombinatoRx R&D Pipeline, August 2008
- Immuno-inflammatory
- CRx-102
- CRx-139
- Pain
- CRx-170
- Dermatology
- CRx-191
- CRx-197
- Metabolism
- Table of Contents
- CRx-401
- Other Research Programmes
- Technologies
- Drug Discovery Platforms
- Patents
- Agreements
- Sosei
- Accelerate B rain Cancer Cure (ABC2)
- The National Institutes of Allergy and Infectious Diseases
- HenKan Pharmaceutical Company
- Angiotech Pharmaceuticals
- Bio*One Capital
- Fovea Pharmaceuticals S A
- Cystic F ibrosis F oundation Therapeutics
- Cure Huntington's Disease Initiative
- Charleys F und/The Nash Avery F oundation
- Spinal M uscular Atrophy F oundation (SM A F oundation)
- SAIC - National Institute of Neurological Disorders and S troke
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Deltanoid Pharmaceuticals
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Osteoporosis
- 2MD
- Agreements
- Abbott
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Diatos
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Diatos R&D Pipeline, August 2008
- Oncology
- DaunoXome
- DTS-301
- DTS-201
- DTS-108
- Technologies
- Drug Development Platforms
- Agreements
- Gilead S ciences
- MacroMed
- Table of Contents
- Medarex
- Universit catholique de Louvain
- Institut Pasteur
- Servier
- OctoPlus Technologies
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Evotec
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Evotec R&D Pipeline, August 2008
- Central Nervous S ystem
- EVT 201
- EVT 101
- EVT 103
- EVT 302
- VR1 Antagonist Programme
- P2X3 and P2X2/3 Antagonist Programme
- B1 antagonists
- H3 antagonists
- BACE inhibitors
- Inflammatory Disease
- P2X7 Antagonist Programme
- MK2 inhibitors
- Oncology
- Hsp90 inhibitors
- Bcl-2, Bcl-xL and Mcl-1 inhibitors
- Technologies
- High-throughput S creening (HTS) Technology
- EVOlution platform
- Patents
- Agreements
- Boehringer Ingelheim
- Roche
- Cure Huntingdons Disease Initiative (CHDI)
- Ono Pharmaceutical
- InterMune
- Takeda
- Interprotein Corporation
- Other Research Contracts
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Five Prime Therapeutics
- Key Personnel
- Company Overview
- Table of Contents
- Milestones
- R&D Pipeline
- FivePrime Therapeutics R&D Pipeline, August 2008
- Oncology
- FP-1039
- FPT040
- FPA005
- FPT069
- Metabolism
- FPT038
- Cardiology
- FPT033/FPT057
- Gastrointestinal
- FPT042/FPT046
- Immunology
- FPT025
- Technologies
- Drug Discovery Platforms
- Agreements
- Gene Logic
- Biosite
- Boehringer Ingelheim
- Centocor/Johnson & Johnson
- Pfizer
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Genmab A/S
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Genmab R&D Pipeline, August 2008
- Oncology
- HuMax-CD4 (zanolimumab)
- HuMax-CD20 (ofatumumab)
- HuMax-EGFr (zalutumumab)
- R1507
- HuMax-IL8
- HuMax-CD38
- HuMax-CD32b
- Autoimmune/Anti-inflammatory
- HuMax-CD20 (ofatumumab)
- AMG 714
- HuMax-IL8
- HuMax-TAC
- Neurology
- HuMax-CD20 (ofatumumab)
- Dermatology
- HuMax-IL8
- Table of Contents
- HuMax-TAC
- Respiratory
- Roche 4
- Virology
- HuMax-HepC
- Transplant Rejection
- HuMax-TAC
- Undisclosed Indications
- Roche 2
- Roche 3
- Technologies
- Antibody Discovery Engine
- Antibody Centre of Excellence
- UniBody
- Patents
- Agreements
- Amgen
- ACE B ioSciences
- Bionomics
- Cytokine PharmaSciences
- Ganymed Pharmaceuticals
- GlaxoSmithKline
- Medarex
- Merck S erono
- Roche
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Ideni x Pharmaceuticals
- Key Personnel
- Company Overview
- Milestones
- Marketed Products
- R&D Pipeline
- Idenix Pharmaceuticals R&D Pipeline, August 2008
- Virology
- IDX184
- IDX899
- IDX375
- IDX136/IDX316 Macrocyclic Protease Inhibitors
- Discontinued Products
- Valopicitabine/NM283
- Patents
- Agreements
- Metabasis Therapeutics
- Novartis Pharma
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- Table of Contents
Ikaria
- Key Personnel
- Company Overview
- Milestones
- Marketed Products
- R&D Pipeline
- Ikaria R&D Pipeline, August 2008
- Cardiology
- INOMax
- IK-1001
- Immunology
- Covox
- Other Research Programmes
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Infinity Pharmaceuticals
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Infinity Pharmaceuticals R&D Pipeline, August 2008
- Oncology
- Retaspimycin
- IPI-493
- IPI-926
- Bcl-2 Protein Inhibitors
- Technologies
- Diversity Oriented S ynthesis Technologies
- Patents
- Agreements
- MedImmune/AstraZeneca
- Novartis
- Amgen
- Johnson & Johnson
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Intercyte x
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Intercytex R&D Pipeline, August 2008
- Dermatology
- ICX-PRO (cyzact)
- VAVELTA
- ICX-TRC
- ICX-SKN
- Table of Contents
- Technologies
- Agreements
- Baxter Healthcare
- The Automation Partnership
- Armed F orces Institute of Regenerative M edicine
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Ironwod Pharmaceuticals
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Ironwood Pharmaceuticals R&D Pipeline, August 2008
- Gastrointestinal
- MD-1100/linaclotide
- Cardiology
- MD-0727
- Agreements
- Forest Laboratories
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
KAI Pharmaceuticals
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- KAI Pharmaceuticals, August 2008
- Cardiology
- KAI-9803
- KAI-1455
- Pain M anagement
- KAI-1678
- Gamma PKC
- Ophthalmology
- Beta PKC
- Inflammatory Disease
- Theta PKC Inhibition
- Agreements
- Sankyo
- Bristol-Myers S quibb
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Kalypsys
- Key Personnel
- Company Overview
- Table of Contents
- Milestones
- R&D Pipeline
- Kalypsys R&D Pipeline, August 2008
- Metabolism
- KD3010
- KD3020
- Pain
- KD7040
- Oncology
- KD5170
- Technologies
- Agreements
- Merck & Co
- CV Therapeutics
- Los Alamos National Laboratory
- National Institutes of Health
- NovImmune
- Eidogen-Sertanty
- Alcon
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Kereos
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Kereos R&D Pipeline, August 2008
- Oncology
- KI-0001
- KI-100X
- KM-4419
- Cardiology
- KI-0002
- KI-1004
- Technologies
- Ligand-Targeted Emulsion Technologies
- Agreements
- Philips
- Lantheus M edical Imaging (Bristol-Myers S quibb M edical Imaging)
- Dow Chemical
- Washington U niversity
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Micromet
- Key Personnel
- Company Overview
- Milestones
- Table of Contents
- R&D Pipeline
- Micromet R&D Pipeline, August 2008
- BiTE Antibody Only Pipeline
- Oncology
- MT103/MEDI-538
- Adecatumumab (MT201)
- MT293 (D93/TRC093)
- MT110
- MT111
- MT228 (MORAb-028)
- bscEphA2xCD3
- muS110
- Antibodies targeting CD33 and MCSP
- Inflammatory/Autoimmune Diseases
- MT203
- MT204
- Technologies
- BiTE (Bispecific T-Cell Engagers) Technology
- Single Chain Antibodies
- Patents
- Agreements
- Enzon Pharmaceuticals
- Abbott, Alligator B ioscience AB, Haptogen and A N Other
- Cambridge Antibody Technology (CAT)
- ESB ATech AG
- MedImmune
- Serono
- EvoGenix Pty
- Novuspharma S pA
- TRACON Pharmaceuticals
- Morphotek
- Nycomed
- University of S outhern California
- Applied M olecular Evolution/Eli Lilly
- Arizeke Pharmaceuticals
- Antigenics
- Viventia B arbados
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Molecular Insight Pharmaceuticals
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Molecular Insight R&D Pipeline, August 2008
- Oncology
- Azedra
- Onalta
- Solazed
- Table of Contents
- Trofex
- Cardiology
- Zemiva
- MIP-190
- Neurology
- MIP-170D
- Technologies
- Ultratrace Technology
- SAAC Technology
- SAACQ Technology
- Nanotrace Discovery
- Patents
- Agreements
- Bayer S chering Pharma
- Novartis Pharma
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Neuromed Pharmaceuticals
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Neuromed Pharmaceuticals Pipeline, August 2008
- Pain
- NMED-160
- NMED-1077
- Others
- Other Indications
- Agreements
- Merck & Co
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Novexel
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Novexel R&D Pipeline, August 2008
- Antibacterial
- NXL103
- NXL101
- NXL104
- NXL105
- Antifungal
- NXL201
- Agreements
- Indevus Pharmaceuticals
- Table of Contents
- Forest Laboratories
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
NPS Pharmaceuticals
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- NPS Pharmaceuticals R&D Pipeline, August 2008
- Gastrointestinal
- GATTEX
- Musculoskeletal
- PREOS/Preotact
- calcilytics
- Central Nervous S ystem
- NPSP156
- Metabolism
- NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection)
- Renal
- Cinacalcet HCl
- Patents
- Agreements
- Amgen
- Kirin Pharma
- Nycomed
- DRI Capital
- GlaxoSmithKline
- Janssen
- AstraZeneca
- Ortho-McNeil Pharmaceuticals
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Optimer Pharmaceuticals
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Optimer Pharmaceuticals R&D Pipeline, August 2008
- Antibacterial
- OPT-80
- Prulifloxacin (OPT-99)
- OPT-1068/CEM-101
- Musculoskeletal
- OPT-88
- Oncology
- OPT-822/OPT-821
- Technologies
- Table of Contents
- Drug Discovery Platform
- Patents
- Agreements
- C&O Pharmaceutical Technology (Holdings)
- Par Pharmaceutical
- Biocon
- Nippon S hinyaku
- Sloan-Kettering Institute for Cancer Research
- Cempra Pharmaceuticals
- The S cripps Research Institute
- Inc Research
- National Institute of Allergy and Infectious Diseases
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Palatin Technologies
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Palatin Technologies R&D Pipeline, August 2008
- Cardiology
- Bremelanotide
- PL-6983
- Natriuretic Receptor Compounds/PL-3994
- Metabolism
- Melanocortin-based Therapeutics
- Imaging/Diagnosis
- NeutroSpec
- Technologies
- Drug Development Platforms
- MIDAS Drug Development Platform
- NeutroSpec
- Patents
- Agreements
- AstraZeneca
- Mallinckrodt
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
PharmaMar
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- PharmaMar R&D Pipeline, August 2008
- Oncology
- Yondelis (trabectedin)
- Aplidin (plitidepsin)
- Table of Contents
- PM02734
- Kahalalide F
- Zalypsis
- Thiocoraline
- Variolins
- Lamellarins
- Dermatology
- Kahalalide F
- Agreements
- Johnson & Johnson
- Innovex
- Swedish Orphan International
- Genesis Pharma
- Cenit-Nanopharma Consortium
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Prana Biotechnology
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Prana Biotechnology R&D Pipeline, August 2008
- Central Nervous S ystem
- PBT2
- Drug Candidate
- Amyloid-inhibiting compounds
- Immunotherapy
- MAbs against Abeta
- Oncology
- PBT1/others
- Ophthalmology
- MPAC Compounds
- Discontinued Products
- Central Nervous S ystem
- PBT1 (Clioquinol)
- Patents
- Agreements
- Schering AG
- * Australian Industry Research and Development Board
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Replidyne
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Replidyne R&D Pipeline, August 2008
- Table of Contents
- Antibacterial
- Faropenem medoxomil
- REP3123/REP8839
- DNA Replication Inhibitors Programme
- Patents
- Agreements
- Forest Laboratories
- Asubio Pharma
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
S*BIO
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Clinical Trials
- HDAC
- Kinase Programme
- S*BIO R&D Pipeline, 2008
- Technology
- Agreements
- A*STAR
- Genome Institute of S ingapore
- Karolinska Institutet
- National U niversity Hospital, Singapore
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Sosei
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Sosei R&D Pipeline, August 2008
- Respiratory S ystem
- NVA237
- QVA149
- Oncology
- AD923
- Central Nervous S ystem
- AD337
- SD118
- Inflammation and Immunology
- SD726
- SD208
- Womens Healthcare
- SOH-075
- Agreements
- Table of Contents
- Mundipharma
- Sandoz
- CombinatoRx
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Spedel Pharmaceuticals
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Speedel R&D Pipeline, August 2008
- Cardiology
- SPP100 (aliskiren,Tekturna, Rasilez)
- SPP200 (pegmusirudin)
- SPP301 (avosentan)
- SPP600
- SPP635
- SPP676
- SPP800 Series
- SPP1100 Series
- SPP2000 Series
- Agreements
- Locus Pharmaceuticals
- Novartis
- Roche
- Abbott Laboratories
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Synta Pharmaceuticals
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Synta Pharmaceuticals R&D Pipeline, August 2008
- Oncology
- STA-4783 (elesclomol)
- STA-9090
- STA-9584
- STA-5312
- Inflammatory Disease
- STA-5326 (apilimod mesylate)
- Crohns Disease
- Rheumatoid Arthritis
- Common Variable Immunodeficiency
- Psoriasis
- CRAC ion channel inhibitor
- Technologies
- Table of Contents
- Chemical Library
- Screening Assays
- In vivo Testing Capabilities
- Chemistry Capabilities
- Target Elucidation
- Patents
- Agreements
- GlaxoSmithKline
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Syntaxin
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Syntaxin R&D Pipeline, August 2008
- Pain
- Un-named Product
- Respiratory
- SYN187
- Other
- Endocrinology Products
- Obesity Products
- Nerve Disorder Products
- Agreements
- Allergan
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Takara Bio
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Oncology
- HSV-TK gene therapies
- T-cell receptor (TCR) gene therapy
- Cancer Immunotherapy
- Cancer Immunity Reconstruction Therapy
- Virology
- VRX496
- MazF Gene Therapy
- Technologies
- Research Reagents and S cientific Instruments
- Contract Research S ervices
- Agreements
- InVivoScribe Technologies
- Memorial S loan-Kettering Cancer Center
- Table of Contents
- Peter M acCallum Cancer Centre
- Green Cross Corporation
- New England B iolabs
- Transgenomic
- Kemp B iotechnologies
- Tianjin M edical U niversity
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Theravance
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Theravance R&D Pipeline, August 2008
- Antibacterial
- Telavancin
- TD-1792
- Respiratory
- GW642444
- GW685698
- GSK159797
- GSK1160724
- GSK656398
- GSK961081
- Gastrointestinal
- TD-5108
- TD-2749
- TD-6301
- Patents
- Agreements
- Astellas
- GlaxoSmithKline
- AstraZeneca
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Tranzyme Pharma
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Tranzyme Pharma R&D Pipeline, August 2008
- Gastrointestinal
- TZP-101
- TZP-102
- TZP-201
- TZP-301
- Technologies
- Table of Contents
- Drug Discovery Platform
- Macrocyclic Template Chemistry (MATCH)
- Patents
- Agreements
- Neokimia/Trimeris
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Trimeris
- Key Personnel
- Company Overview
- Milestones
- Marketed Products
- Virology
- FUZEON
- R&D Pipeline
- Virology
- FUZEON
- TRI-1144
- Patents
- Agreements
- Roche
- Array B iopharma
- Neokimia/Tranzyme
- ChemBridge Research Laboratories
- New Y ork B lood Center
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Trubion Pharmaceuticals
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Trubion Pharmaceuticals R&D Pipeline, August 2008
- Autoimmune/Inflammatory Diseases
- TRU-015
- SBI-087
- Oncology
- TRU-015
- TRU-016
- Technologies
- Product Engine
- Patents
- Agreements
- Wyeth
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Table of Contents
- Corporate Environment
Viro Pharma
- Key Personnel
- Company Overview
- Milestones
- Marketed Products
- Antibacterial
- Vancocin
- R&D Pipeline
- ViroPharma R&D Pipeline, August 2008
- Virology
- Maribavir (CAMVIA)
- CDI Programme
- Anti-inflammatory
- C1 inhibitor (human)
- Discontinued Products
- Virology
- Picovir (Pleconaril)
- Hepatitis C Candidates
- HCV371
- HCV-086
- HCV-796
- Patents
- Agreements
- GlaxoSmithKline
- Sanofi-Synthlabo/sanofi-aventis
- Schering-Plough
- Eli Lilly
- Wyeth
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
WILEX
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- WILEX R&D Pipeline, August 2008
- Oncology
- WX-G250 and WX-G250RIT (RENCAREX)
- WX-UK1
- K931
- WX-671 (MESUPRON)
- CA9-SCAN (REDECTANE)
- WX-77X Series
- Patents
- Agreements
- Centocor
- Bayer
- VU U niversity M edical Center Amsterdam
- Table of Contents
- Fox Chase Cancer Center
- Esteve
- IBA M olecular
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
Xencor
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Xencor R&D Pipeline, August 2008
- Inflammatory Disease
- XPro1595
- Oncology
- XmAb2513
- Oncology/Inflammatory Disease
- XmAb5574
- XmAb5871
- XmAb5485
- Technologies
- Protein Design Automation
- XPro
- XmAb technology
- ImmunoPDA
- Patents
- Agreements
- Caltech
- Torrey M esa Research Institute
- Protein Design Labs
- Eli Lilly
- Genentech
- Chugai Pharmaceutical
- Centocor
- MedImmune
- Roche
- Boehringer Ingelheim
- Human Genome S ciences
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- Espico m Anal ysis
- Winners & Losers
- Biopharmaceutical Company R&D Pipelines
- Phase III Drug Candidates
- Phase III Drug Candidates
- Methodology
- Company Ratings
- Section Name